XenoPort, Inc.

UPDATE: Deutsche Bank Reiterates Buy, Lowers PT on XenoPort on Disappointing Results

XenoPort weakness creates buying opportunity, says Wells Fargo

XenoPort's CEO Presents at Special Conference (Transcript)

UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral

XenoPort downgraded to Neutral from Outperform at Wedbush

XenoPort, Inc. Drops Multiple Sclerosis Drug After Trial Failure; Stock Drops -0.85(12.60%) @ 10:17AM ET

Pre-market Movers For May 20 (YHOO, WCRX, ACT, WBSN, CHK, PXP, XNPT, PPHM)

XenoPort (XNPT) Arbaclofen Placarbil Phase 3 Misses Endpoints

XenoPort to host conference call

XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients